View Older Stories View More Recent Stories

Jun 17, 2025 09:50AM SRPT Alert: Kehoe Law Firm, P.C. Investigating Potential Securities Fraud Claims on Behalf of Investors of Sarepta Therapeutics, Inc
Jun 17, 2025 07:14AM Goldman Sachs Downgrades Sarepta Therapeutics (SRPT) to Neutral
Jun 17, 2025 05:54AM Wolfe Research Starts Sarepta Therapeutics (SRPT) at Peerperform
Jun 16, 2025 05:22PM Sarepta Therapeutics (SRPT) PT Lowered to $62 at TD Cowen
Jun 16, 2025 02:47PM Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight
Jun 16, 2025 02:04PM Sarepta Therapeutics (SRPT) call put ratio 2.1 calls to 1 put with a focus on August 60 and 70 calls as share price down 43%
Jun 16, 2025 11:07AM BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
Jun 16, 2025 10:06AM BofA Securities Downgrades Sarepta Therapeutics (SRPT) to Neutral
Jun 16, 2025 08:57AM UBS Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
Jun 16, 2025 08:45AM Sarepta shares under pressure, analysts flag risks after second Elevidys-linked death
Jun 16, 2025 07:00AM Sarepta Therapeutics (SRPT) Provides Safety Update for ELEVIDYS
Jun 16, 2025 06:35AM H.C. Wainwright Downgrades Sarepta Therapeutics (SRPT) to Sell
Jun 16, 2025 05:14AM Stocks expected to have increasing option volume: SRPT CCL SATS X
Jun 16, 2025 05:09AM Sarepta Therapeutics (SRPT) 30-day option implied volatility is at 74 into share price lower before the bell
Jun 16, 2025 03:11AM BMO Capital Downgrades Sarepta Therapeutics (SRPT) to Market Perform
Jun 16, 2025 02:37AM Piper Sandler Downgrades Sarepta Therapeutics (SRPT) to Neutral
Jun 6, 2025 07:07AM Scotiabank Upgrades Sarepta Therapeutics (SRPT) to Sector Outperform, 'Attractive Risk Reward Ahead of Important Catalysts'
Jun 5, 2025 10:36AM Regenxbio DMD data should have no impact on Sarepta Therapeutics (SRPT), especially at this price - BMO Capital
Jun 4, 2025 09:31AM Sarepta Therapeutics (SRPT) Granted FDA Platform Technology Designation to the Viral Vector Used in SRP-9003
May 28, 2025 05:07AM Goldman Sachs on Sarepta Therapeutics (SRPT): 'Elevidys' full approval is likely intact per CBER Director's commentary'
May 21, 2025 08:39AM Sarepta Therapeutics (SRPT) Gains 5pct on UK Dosing Update in ENVISION
May 21, 2025 08:31AM Sarepta Therapeutics (SRPT) Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
May 16, 2025 09:01AM Sarepta Therapeutics (SRPT) Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
May 13, 2025 10:58AM Morgan Stanley on Sarepta (SRPT): 'Elevidys Approval in Japan Further Confirms Favorable Benefit/Risk Profile'
May 13, 2025 09:25AM Sarepta Therapeutics (SRPT) Announces Approval in Japan of ELEVIDYS
May 8, 2025 06:30AM Evercore ISI Downgrades Sarepta Therapeutics (SRPT) to In Line, 'Near-Term Catalysts Won't Alleviate Key Concerns'
May 7, 2025 09:55AM Sarepta Therapeutics (SRPT) PT Slashed to $137 at TD Cowen
May 7, 2025 09:32AM Sarepta Therapeutics (SRPT) PT Lowered to $81 at Cantor Fitzgerald
May 7, 2025 09:31AM Sarepta Therapeutics (SRPT) PT Lowered to $58 at RBC Capital as 'Elevidys Hits A Wall'
May 7, 2025 09:14AM Sarepta Therapeutics (SRPT) PT Lowered to $120 at BMO Capital
May 7, 2025 07:16AM Sarepta Therapeutics (SRPT) PT Lowered to $40 at H.C. Wainwright
May 7, 2025 05:36AM Sarepta Therapeutics (SRPT) call put ratio 1 call to 1 put amid wide price movement
May 6, 2025 04:49PM After-hours movers: AMD, Marvell Tech, Super Micro Computer and more
May 6, 2025 04:19PM Sarepta Therapeutics (SRPT) Lowers Guidance
May 6, 2025 02:28PM Sarepta Therapeutics (SRPT) Weakness Tied to FDA Appointee
Apr 21, 2025 10:26AM Sarepta Therapeutics (SRPT) PT Slashed at Piper Sandler Following Survey Results
Apr 15, 2025 08:31AM Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
Apr 11, 2025 06:50AM Wells Fargo Starts Sarepta Therapeutics (SRPT) at Overweight 'on DMD Commercial Opportunities'
Apr 10, 2025 07:10AM Sarepta Therapeutics (SRPT) PT Lowered to $112 at Guggenheim
Apr 7, 2025 08:25AM Sarepta Therapeutics (SRPT) PT Lowered to $184 at Oppenheimer
Apr 7, 2025 06:40AM H.C. Wainwright Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
Apr 4, 2025 12:28PM Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Apr 4, 2025 08:44AM Sarepta Therapeutics (SRPT) Provides Update on ELEVIDYS
Apr 3, 2025 07:13AM Sarepta Therapeutics (SRPT) PT Lowered to $183 at Needham
Apr 2, 2025 06:37AM H.C. Wainwright Upgrades Sarepta Therapeutics (SRPT) to Neutral
Apr 1, 2025 10:00AM RBC makes changes to its flagship 'Top 30 Global Ideas for 2025' list
Mar 19, 2025 10:17AM UBS Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
Mar 19, 2025 06:41AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
Mar 19, 2025 06:34AM Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Mar 19, 2025 06:00AM Mizuho sees a compelling buying opportunity in this beaten-down biotech stock
View More Recent Stories View Older Stories